RecruitingNCT07155148
Argentine Registry of Crohn's Disease and Ulcerative Colitis
Sponsor
Grupo Argentino de Enfermedad de Crohn y Colitis Ulcerosa
Enrollment
4,250 participants
Start Date
Jul 14, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
RADECCU is a strictly observational IBD registry in Argentina. The registry is open to all practicing gastroenterologist in the country grouped within the Argentinean Crohn's and Ulcerative Colitis Group (GADECCU). The registry will include outcomes of routine clinical practice of patients with IBD including the pediatric and adult population.
Eligibility
Inclusion Criteria1
- Any patient diagnosed with IBD defined by validated diagnostic criteria can be included into the registry. The criteria for IBD diagnosis were based on previously published criteria for IBD diagnosis, including clinical, endoscopic, laboratory, and histopathological aspects, as well as small bowel imaging studies
Exclusion Criteria2
- Suspected IBD diagnosis without confirmation
- IBD patients with incomplete information about therapy and follow-up
Interventions
OTHERobservational study
Observational registry without clinical interventions
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07155148
Related Trials
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
NCT072375165 locations
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
NCT0711352266 locations
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
NCT072453949 locations
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
NCT073851311 location
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
NCT048066201 location